ערך בספרים למניה: biopathholdings.com (BPTH)

Management's focus on advancing clinical trials against leukemias sparked momentum captured by the GURU.Markets service's base chart regarding Bio-Path Holdings (BPTH) book value per share, where the -0.19 mark records this metric. This confirms the value of the DNAbilize platform, which creates a patent perimeter for therapy, and the development of nanoparticles to neutralize tumor proteins within the RNA treatment ecosystem.

Book value per share reflects the actual value of the issuer's net assets, calculated as the difference between total assets and liabilities divided by the number of shares outstanding. Analyzing the book value per share allows for an assessment of the internal reserves of Bio-Path Holdings (BPTH), which is critical when financing large-scale clinical trials of the DNAbilize platform to capture the oncohematology market.